| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
M Kathleen Behrens is Director at SRPT and has filed Form 4s across 2 companies. M Kathleen Behrens's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.7M at current prices.
The biggest single holding is SRPT (~$4.0M) as Director. Net of sales, the SRPT filings show accumulation of 62,500 shares.
M Kathleen Behrens has 30 Form 4 filings on record from February 2015 to June 2026, across 2 companies: Director at Sarepta Therapeutics (SRPT), 2015–2026; Director at Mimedx Group (MDXG), 2020–2025.
The 47 reported transactions were 20 stock awards, 12 option or other derivative awards, 8 option exercises and 3 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $1.4M and 2 sales worth about $1.7M.
The largest open-market purchase was 75,000 shares of SRPT at an average $16.28 on March 16, 2016, about $1.2M.
The largest open-market sale was 10,000 shares of SRPT at an average $131.71 on October 31, 2018, about $1.3M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2021 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 5,000 | $85.76 | $428,800.00 | -3.7% | -7.3% | -4.2% | |
| Sep 6, 2019 | SRPT Sarepta Therapeutics, Inc. | Director | Buy | 2,500 | $87.98 | $219,950.00 | +2.0% | - | - | |
| Oct 31, 2018 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 10,000 | $131.71 | $1,317,100.00 | -7.9% | - | - | |
| Mar 16, 2016 | SRPT Sarepta Therapeutics, Inc. | Director | Buy | 75,000 | $16.28 | $1,220,708.50 | -141.1% | - | - |